New Cholesterol Treatment Standard Could Slash Cardiovascular Deaths
In ground-breaking research published in the Mayo Clinic Proceedings, a new standard of treatment for “bad” cholesterol, or LDL-C, promises significant reductions in cardiovascular mortality and morbidity, potentially preventing over 330,000 deaths annually worldwide. The study, led by experts from the Polish Lipid Association, represents the most extensive meta-analysis on cholesterol management to date and highlights the substantial benefits of combining statin therapy with the drug ezetimibe for high-risk patients.